Literature DB >> 9761892

Crystallization and preliminary X-ray analysis of tetanus neurotoxin C fragment.

T C Umland1, L Wingert, S Swaminathan, J J Schmidt, M Sax.   

Abstract

Two crystal forms of recombinant tetanus neurotoxin C fragment have been obtained. The C fragment corresponds to the C-terminal 451 amino-acid residues of tetanus neurotoxin and is the subunit responsible for receptor binding by the toxin. Both forms belong to space group P212121. Form I has unit-cell dimensions of a = 71.3, b = 79.7, c = 94.0 A and produces thin plate crystals. Form II has unit-cell dimensions of a = 67.4, b = 79.7, c = 91.1 A and produces thick rod-shaped crystals. Diffraction data to 2.6 A have been collected from form II crystals.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9761892     DOI: 10.1107/s0907444997009025

Source DB:  PubMed          Journal:  Acta Crystallogr D Biol Crystallogr        ISSN: 0907-4449


  4 in total

1.  A conformational change of C fragment of tetanus neurotoxin reduces its ganglioside-binding activity but does not destroy its immunogenicity.

Authors:  Rui Yu; Shaoqiong Yi; Changming Yu; Ting Fang; Shuling Liu; Ting Yu; Xiaohong Song; Ling Fu; Lihua Hou; Wei Chen
Journal:  Clin Vaccine Immunol       Date:  2011-08-03

2.  Characterisation of a panel of anti-tetanus toxin single-chain Fvs reveals cooperative binding.

Authors:  Nathan Scott; Omar Qazi; Michael J Wright; Neil F Fairweather; Mahendra P Deonarain
Journal:  Mol Immunol       Date:  2010-04-22       Impact factor: 4.407

3.  Comparative Immunogenicity of the Tetanus Toxoid and Recombinant Tetanus Vaccines in Mice, Rats, and Cynomolgus Monkeys.

Authors:  Rui Yu; Ting Fang; Shuling Liu; Xiaohong Song; Changming Yu; Jianmin Li; Ling Fu; Lihua Hou; Junjie Xu; Wei Chen
Journal:  Toxins (Basel)       Date:  2016-06-25       Impact factor: 4.546

4.  Safety and Immunogenicity of a Recombinant Tetanus Vaccine in Healthy Adults in China: A Randomized, Double-Blind, Dose Escalation, Placebo- and Positive-Controlled, Phase 1/2 Trial.

Authors:  Xiaowei Xu; Rui Yu; Lanlan Xiao; Jie Wang; Meihong Yu; Junjie Xu; Yajun Tan; Xiao Ma; Xiaoxin Wu; Jiangshan Lian; Kaizhou Huang; Xiaoxi Ouyang; Sheng Bi; Shipo Wu; Xiaoyan Wang; Jiandi Jin; Ling Yu; Huafen Zhang; Qi Wei; Jinfa Shi; Wei Chen; Lanjuan Li
Journal:  Adv Sci (Weinh)       Date:  2021-06-03       Impact factor: 16.806

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.